Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
11/07/2025 07:00 AM • Prime Medicine reported Q3 2025 financial results, highlighting progress in genetic therapies for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with plans to file IND/CTA applications in 2026-2027 and new preclinical data to be presented at AASLD.
PRME - Company showed progress in pipeline development, nominated new development candidates, strengthened leadership, maintained financial runway into 2027, and presented promising preclinical data
Investing.com • Brett Owens